Caladrius Bioscience To Start Testing Its CD34+ Cell Therapy in Diabetic Kidney Disease

by Vandana Singh, Benzinga Editor

June 22, 2021 10:51 AM | 22 seconds read | Make a Comment

The FDA has signed off Caladrius Bioscience Inc's CLBS investigational new drug application for the study of CLBS201 for the treatment of diabetic kidney disease ("DKD").
The company plans to initiate a Phase 1/2 proof-of-concept study of CLBS201 within the next several months.
Price Action: CLBS shares are up 0.06% at $1.56 during the market session on the last check Tuesday.

Posted In: Biotech News Penny Stocks Health Care FDA General Briefs Kidney Diseases

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.